1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Senior decision-makers in healthcare and life sciences are navigating an increasingly complex landscape shaped by advances in vasopressin antagonists. This evolving market is characterized by next-generation selective therapies, integrated digital solutions, and dynamic regulatory and cost pressures—all driving innovation and strategic realignment for leading stakeholders.
Market Snapshot: Vasopressin Antagonist Segment
The global vasopressin antagonist market is undergoing significant transformation, driven by heightened clinical demand and expanding therapeutic applications. Market progress is supported by a shift toward receptor-specific compounds and multimodal delivery systems. Regulatory developments and adaptive pricing frameworks continue to shape adoption curves, especially in major economies. Strong clinical trial pipelines and investments across North America, Europe, and Asia-Pacific underscore robust long-term growth potential.
Scope & Segmentation: Defining Market Coverage
- Mechanism of Action: Non-selective V1a V2 receptor antagonists, Selective V2 receptor antagonists
- Product Types: Injectable formulations, Oral therapies
- Route of Administration: Intravenous, Oral
- Dosage Forms: Lyophilized powder, Tablets
- Distribution Channels: Hospital pharmacy, Online pharmacy, Retail pharmacy
- Indications: Congestive heart failure (preserved and reduced ejection fraction), Liver cirrhosis (compensated, decompensated), Syndrome of inappropriate antidiuretic hormone secretion
- Regional Coverage: Americas (United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
- Company Analysis: Otsuka Pharmaceutical Co., Ltd.; Astellas Pharma Inc.; Pfizer Inc.
Key Takeaways: Strategic Insights for Vasopressin Antagonist Decision-Makers
- Vasopressin antagonists demonstrate increasing clinical value in cases of water regulation disorders, with selective V2 inhibition now a primary strategy for reducing off-target effects.
- Adoption of personalized medicine is strengthening, as stratified clinical trials identify patient populations that benefit most from tailored therapies.
- Integrating real-time digital health monitoring is helping optimize dosing and support adaptive trial design, driving improved adherence and streamlined approval pathways.
- Distribution models are shifting, with injectable agents preferred in acute care and oral therapies facilitating outpatient management and improved patient quality of life.
- Collaborations between innovators, contract development organizations, and generic manufacturers are essential for accelerating bioequivalence, expanding access, and prolonging product lifecycles.
Tariff Impact: Navigating US Trade Policy Shifts
The introduction of revised United States tariffs has meaningfully altered vasopressin antagonist supply chains and manufacturing costs. Manufacturers face higher sourcing expenses for active pharmaceutical ingredients, prompting shifts toward domestic production. Compliance teams must manage increased documentation and adapt to changing exemptions, as cost containment initiatives trigger new pricing and reimbursement negotiations. Companies are adopting value-based agreements and exploring differentiated pricing approaches to align market access with economic constraints.
Methodology & Data Sources
Analysis is based on a blend of secondary and primary methodologies. Peer-reviewed journals, regulatory filings, clinical trial registries, and public disclosures formed the secondary research backbone. Primary sources include interviews with industry executives, clinicians, pharmacists, and supply chain experts, ensuring perspectives from all key market stakeholders. Triangulation of data underpins the reliability of insight and scenario modeling delivers actionable foresight. Strict confidentiality and ethical best practices guide all findings.
Why This Report Matters
- The report equips leaders with actionable strategies to enhance pipeline differentiation and leverage digital integration for competitive positioning.
- Coverage of tariffs, segmentation dynamics, and regional investments enables data-driven decisions on resource allocation and pricing models.
- Access to nuanced analysis of clinical and commercial innovation pathways helps organizations align product portfolios with evolving market needs.
Conclusion
Vasopressin antagonists are reshaping clinical and market paradigms through selective therapeutics, targeted delivery formats, and strategic industry alliances. This report provides executive teams with the frameworks needed to anticipate change, mitigate risk, and advance growth opportunities in this competitive therapeutic field.
This product will be delivered within 1-3 business days.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of phase III clinical trials evaluating selective V1a receptor antagonists in chronic heart failure management among elderly patients
5.2. Integration of genomic biomarker assays to personalize tolvaptan dosing strategies in patients with syndrome of inappropriate antidiuretic hormone secretion
5.3. Emergence of oral non-peptide vasopressin antagonists featuring improved bioavailability and minimized hepatic toxicity risks
5.4. Regulatory clearance for fixed dose combinations of vasopressin antagonists with loop diuretics in acute decompensated heart failure treatment
5.5. Adoption of real world evidence from observational studies to influence payer coverage decisions for aquaretic therapies in hyponatremia management
5.6. Development of once weekly sustained release vasopressin antagonist formulations for pediatric central diabetes insipidus patients
5.7. Strategic alliances between biotech startups and CDMOs to accelerate GMP manufacturing scale up of selective V2 receptor blockers
5.8. Launch of digital health platforms integrating patient monitoring and adherence support for outpatient vasopressin antagonist therapy regimens
5.2. Integration of genomic biomarker assays to personalize tolvaptan dosing strategies in patients with syndrome of inappropriate antidiuretic hormone secretion
5.3. Emergence of oral non-peptide vasopressin antagonists featuring improved bioavailability and minimized hepatic toxicity risks
5.4. Regulatory clearance for fixed dose combinations of vasopressin antagonists with loop diuretics in acute decompensated heart failure treatment
5.5. Adoption of real world evidence from observational studies to influence payer coverage decisions for aquaretic therapies in hyponatremia management
5.6. Development of once weekly sustained release vasopressin antagonist formulations for pediatric central diabetes insipidus patients
5.7. Strategic alliances between biotech startups and CDMOs to accelerate GMP manufacturing scale up of selective V2 receptor blockers
5.8. Launch of digital health platforms integrating patient monitoring and adherence support for outpatient vasopressin antagonist therapy regimens
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
6.2. PESTLE Analysis
8. Vasopressin Antagonist Market, by Mechanism Of Action
8.1. Introduction
8.2. Non Selective V1a V2 Receptor
8.3. Selective V2 Receptor
8.2. Non Selective V1a V2 Receptor
8.3. Selective V2 Receptor
9. Vasopressin Antagonist Market, by Product Type
9.1. Introduction
9.2. Injectable
9.3. Oral
9.2. Injectable
9.3. Oral
10. Vasopressin Antagonist Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.2. Intravenous
10.3. Oral
11. Vasopressin Antagonist Market, by Dosage Form
11.1. Introduction
11.2. Lyophilized Powder
11.3. Tablets
11.2. Lyophilized Powder
11.3. Tablets
12. Vasopressin Antagonist Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Vasopressin Antagonist Market, by Indication
13.1. Introduction
13.2. Congestive Heart Failure
13.2.1. Preserved Ejection Fraction
13.2.2. Reduced Ejection Fraction
13.3. Liver Cirrhosis
13.3.1. Compensated
13.3.2. Decompensated
13.4. Syndrome Of Inappropriate Antidiuretic Hormone Secretion
13.2. Congestive Heart Failure
13.2.1. Preserved Ejection Fraction
13.2.2. Reduced Ejection Fraction
13.3. Liver Cirrhosis
13.3.1. Compensated
13.3.2. Decompensated
13.4. Syndrome Of Inappropriate Antidiuretic Hormone Secretion
14. Americas Vasopressin Antagonist Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Vasopressin Antagonist Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Vasopressin Antagonist Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Otsuka Pharmaceutical Co., Ltd.
17.3.2. Astellas Pharma Inc.
17.3.3. Pfizer Inc.
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Otsuka Pharmaceutical Co., Ltd.
17.3.2. Astellas Pharma Inc.
17.3.3. Pfizer Inc.
List of Figures
FIGURE 1. VASOPRESSIN ANTAGONIST MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. VASOPRESSIN ANTAGONIST MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. VASOPRESSIN ANTAGONIST MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. VASOPRESSIN ANTAGONIST MARKET: RESEARCHAI
FIGURE 28. VASOPRESSIN ANTAGONIST MARKET: RESEARCHSTATISTICS
FIGURE 29. VASOPRESSIN ANTAGONIST MARKET: RESEARCHCONTACTS
FIGURE 30. VASOPRESSIN ANTAGONIST MARKET: RESEARCHARTICLES
FIGURE 2. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. VASOPRESSIN ANTAGONIST MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. VASOPRESSIN ANTAGONIST MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. VASOPRESSIN ANTAGONIST MARKET: RESEARCHAI
FIGURE 28. VASOPRESSIN ANTAGONIST MARKET: RESEARCHSTATISTICS
FIGURE 29. VASOPRESSIN ANTAGONIST MARKET: RESEARCHCONTACTS
FIGURE 30. VASOPRESSIN ANTAGONIST MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. VASOPRESSIN ANTAGONIST MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY NON SELECTIVE V1A V2 RECEPTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY NON SELECTIVE V1A V2 RECEPTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY SELECTIVE V2 RECEPTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY SELECTIVE V2 RECEPTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY REDUCED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY REDUCED EJECTION FRACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY COMPENSATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY COMPENSATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DECOMPENSATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DECOMPENSATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 97. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 98. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 99. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 100. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 101. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 102. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 103. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 104. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 105. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 108. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 109. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 110. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 111. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 112. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 113. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 114. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 115. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 116. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 117. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 118. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 119. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 120. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 121. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 124. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 125. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 126. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 127. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 195. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 196. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 197. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 198. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 199. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 202. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 203. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 208. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 209. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 211. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 212. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 213. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 214. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 215. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 216. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 217. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 218. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 219. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 224. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 225. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 243. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 244. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 245. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 246. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 247. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 250. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 251. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 254. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 255. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 256. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 257. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 258. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 259. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 260. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 261. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 266. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 267. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 272. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 273. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 274. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 292. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 294. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 307. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 308. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 310. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA VASOPRESSIN ANT
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY NON SELECTIVE V1A V2 RECEPTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY NON SELECTIVE V1A V2 RECEPTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY SELECTIVE V2 RECEPTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY SELECTIVE V2 RECEPTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY REDUCED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY REDUCED EJECTION FRACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY COMPENSATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY COMPENSATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DECOMPENSATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DECOMPENSATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL VASOPRESSIN ANTAGONIST MARKET SIZE, BY SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 97. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 98. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 99. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 100. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 101. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 102. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 103. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 104. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 105. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 108. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 109. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 110. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 111. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 112. CANADA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 113. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 114. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 115. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 116. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 117. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 118. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 119. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 120. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 121. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 124. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 125. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 126. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 127. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 195. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 196. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 197. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 198. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 199. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 202. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 203. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 208. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 209. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 211. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 212. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 213. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 214. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 215. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 216. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 217. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 218. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 219. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 224. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 225. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 243. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 244. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 245. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 246. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 247. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 250. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 251. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 254. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 255. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 256. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 257. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 258. ITALY VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 259. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 260. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 261. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 266. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 267. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 272. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 273. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 274. SPAIN VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 292. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 294. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY CONGESTIVE HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA VASOPRESSIN ANTAGONIST MARKET SIZE, BY LIVER CIRRHOSIS, 2025-2030 (USD MILLION)
TABLE 307. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 308. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 310. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA VASOPRESSIN ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA VASOPRESSIN ANT
Samples
LOADING...
Companies Mentioned
The companies profiled in this Vasopressin Antagonist Market report include:- Otsuka Pharmaceutical Co., Ltd.
- Astellas Pharma Inc.
- Pfizer Inc.
